In this interview with Pharmacy Times, Karen Knudsen, PhD, MBA, CEO of Parker Institute for Cancer Immunotherapy (PICI), discusses major immunotherapy advances being presented at the 2026 ASCO Annual Meeting and their potential impact on cancer care. Knudsen highlights the growing momentum behind therapeutic cancer vaccines, particularly in difficult-to-treat malignancies such as metastatic melanoma, pancreatic cancer, and glioblastoma, as well as continued progress in cell-based therapies for solid tumors. She also emphasizes the expanding role of antibody-drug conjugates (ADCs), rational immunotherapy combinations, and AI-driven immune profiling platforms like PICI’s Radiohead initiative to better predict treatment response and toxicity.

https://www.pharmacytimes.com/view/asco-kickoff-cancer-vaccines-cell-therapies-and-ai-driven-precision-oncology-signal-the-next-era-of-immunotherapy